SPARC rises on USFDA response to drug application

The stock of Sun Pharma Advanced Research Company (SPARC) rose up to 12 per cent on Tuesday after the company said US Food and Drug Administration (FDA) has issued a complete response letter to its New Drug Application (NDA) for Latanoprost BAK-free eyedrops.

The stock closed 9.7 per cent higher on the BSE.

While the FDA did not seek any additional information for supporting clinical data, it sought additional information on certain labeling and other deficiencies for processing the NDA.

SPARC believes that this additional information request from the FDA can be addressed on priority, the company said.